Retevmo
Payments companies reported to CMS as associated with Retevmo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Retevmo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Retevmo
These are the largest totals companies reported as associated with Retevmo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tarek Mekhail | Orlando, FL | Hematology & Oncology | $59,374.06 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $34,930.20 |
| Firas Badin | Lexington, KY | Hematology & Oncology | $33,525.17 |
| Alejandro Calvo | Kettering, OH | Hematology & Oncology | $28,961.99 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $24,914.86 |
| Ari Baron | San Francisco, CA | $24,853.71 | |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $21,429.99 |
| Sandeep Kodityal | Shenandoah, TX | Hematology & Oncology | $18,860.11 |
| Rajesh Kukunoor | Scottsdale, AZ | Hematology & Oncology | $10,751.66 |
| Johnny Chang | Encino, CA | Hematology & Oncology | $10,179.38 |
Prescribed Retevmo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.